Oral Contraceptive Switch Advocates Reject User Age As Approval Factor
This article was originally published in The Pink Sheet
FDA could soon receive an NDA from non-profit research group Ibis Reproductive Health and HRA Pharma, for an oral contraceptive switch in the US.
You may also be interested in...
An HHS draft proposal to broaden the "religious and moral objections" exemption from an Affordable Care Act rule mandating that employers cover employees' contraceptive use in health care plans, threatens US sales of intrauterine devices (IUDs), which total more than $1bn annually.
In a recent letter to drug firms, FDA rejects Plan B One-Step manufacturer Teva’s requests to restrict sales and labeling of generic equivalents. Labeling for the generics will not prevent consumers under 17 from buying the products nor require retailers to ask consumers for proof of age.
Brand’s management says its packaging redesign “was inspired by the Nature Made heritage and Nurish mission that healthy living should be joyful.” It partnered with branding consultancy Spicefire to develop brand and packaging to evoke Pharmavite’s 50 years of providing supplements.